Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis

Mike Wenzel; Marina Deuker; Luigi Nocera; Claudia Collà Ruvolo; Christoph Würnschimmel; Zhe Tian; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Derya Tilki; Markus Graefen; Luis A Kluth; Andreas Becker; Frederik C Roos; Felix K H Chun; Pierre I Karakiewicz

doi:10.1016/j.ejca.2021.07.014

Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis

Standard

Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. / Wenzel, Mike; Deuker, Marina; Nocera, Luigi; Collà Ruvolo, Claudia; Würnschimmel, Christoph; Tian, Zhe; Shariat, Shahrokh F; Saad, Fred; Briganti, Alberto; Tilki, Derya; Graefen, Markus; Kluth, Luis A; Becker, Andreas; Roos, Frederik C; Chun, Felix K H; Karakiewicz, Pierre I.

In: EUR J CANCER, Vol. 155, 09.2021, p. 245-255.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Wenzel, M, Deuker, M, Nocera, L, Collà Ruvolo, C, Würnschimmel, C, Tian, Z, Shariat, SF, Saad, F, Briganti, A, Tilki, D, Graefen, M, Kluth, LA, Becker, A, Roos, FC, Chun, FKH & Karakiewicz, PI 2021, 'Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis', EUR J CANCER, vol. 155, pp. 245-255. https://doi.org/10.1016/j.ejca.2021.07.014

APA

Wenzel, M., Deuker, M., Nocera, L., Collà Ruvolo, C., Würnschimmel, C., Tian, Z., Shariat, S. F., Saad, F., Briganti, A., Tilki, D., Graefen, M., Kluth, L. A., Becker, A., Roos, F. C., Chun, F. K. H., & Karakiewicz, P. I. (2021). Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. EUR J CANCER, 155, 245-255. https://doi.org/10.1016/j.ejca.2021.07.014

Vancouver

Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z et al. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. EUR J CANCER. 2021 Sep;155:245-255. https://doi.org/10.1016/j.ejca.2021.07.014

Bibtex

@article{f1e432c25bf242b2a5c23d49bc28d493,

title = "Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis",

abstract = "BACKGROUND: The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void.MATERIAL AND METHODS: We systematically examined TKI efficacy after IO-failure and generated weighted median progression-free survival (PFS) estimates for Pazopanib, Axitinib, Cabozantinib, Sunitinib. A systematic review according to PRISMA was conducted. PubMed and abstracts were queried. Only studies proving median PFS were included. Weighted medians were computed for each TKI alternative.RESULTS: Of 245 articles, nine eligible studies were included in the current study with 952 analysed patients. Weighted PFS medians after any previous IO-based therapy were respectively 13.7 (range from 4.6 to 24.4), 8.1 (range from 4.7 to 13.2), 8.5 (range from 4.7 to 15.2) and 6.9 months (range from 2.9 to 11.6) for Pazopanib, Axitinib, Cabozantinib, Sunitinib. Specific second-line weighted PFS median was 14.8 months (range from 5.6 to 24.4), 10.1 months (range from 6.4 to 13.2), 8.7 months (range from 4.7 to 15.2) and 6.0 months (range from 2.9 to 8.0) for Pazopanib, Axitinib, Cabozantinib, Sunitinib, respectively, after first-line IO.CONCLUSION: Pazopanib results in the longest weighted median PFS, after previous IO-failure, regardless of treatment line, as well as in specific second-line, post-first-line IO failure settings. Pending novel studies, Pazopanib appears to represent the most promising treatment option after prior IO.",

keywords = "Female, Humans, Kidney Neoplasms/drug therapy, Male, Neoplasm Metastasis, Protein Kinase Inhibitors/pharmacology, Time Factors",

author = "Mike Wenzel and Marina Deuker and Luigi Nocera and {Coll{\`a} Ruvolo}, Claudia and Christoph W{\"u}rnschimmel and Zhe Tian and Shariat, {Shahrokh F} and Fred Saad and Alberto Briganti and Derya Tilki and Markus Graefen and Kluth, {Luis A} and Andreas Becker and Roos, {Frederik C} and Chun, {Felix K H} and Karakiewicz, {Pierre I}",

year = "2021",

month = sep,

doi = "10.1016/j.ejca.2021.07.014",

language = "English",

volume = "155",

pages = "245--255",

journal = "EUR J CANCER",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis

AU - Wenzel, Mike

AU - Deuker, Marina

AU - Nocera, Luigi

AU - Collà Ruvolo, Claudia

AU - Würnschimmel, Christoph

AU - Tian, Zhe

AU - Shariat, Shahrokh F

AU - Saad, Fred

AU - Briganti, Alberto

AU - Tilki, Derya

AU - Graefen, Markus

AU - Kluth, Luis A

AU - Becker, Andreas

AU - Roos, Frederik C

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

PY - 2021/9

Y1 - 2021/9

N2 - BACKGROUND: The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void.MATERIAL AND METHODS: We systematically examined TKI efficacy after IO-failure and generated weighted median progression-free survival (PFS) estimates for Pazopanib, Axitinib, Cabozantinib, Sunitinib. A systematic review according to PRISMA was conducted. PubMed and abstracts were queried. Only studies proving median PFS were included. Weighted medians were computed for each TKI alternative.RESULTS: Of 245 articles, nine eligible studies were included in the current study with 952 analysed patients. Weighted PFS medians after any previous IO-based therapy were respectively 13.7 (range from 4.6 to 24.4), 8.1 (range from 4.7 to 13.2), 8.5 (range from 4.7 to 15.2) and 6.9 months (range from 2.9 to 11.6) for Pazopanib, Axitinib, Cabozantinib, Sunitinib. Specific second-line weighted PFS median was 14.8 months (range from 5.6 to 24.4), 10.1 months (range from 6.4 to 13.2), 8.7 months (range from 4.7 to 15.2) and 6.0 months (range from 2.9 to 8.0) for Pazopanib, Axitinib, Cabozantinib, Sunitinib, respectively, after first-line IO.CONCLUSION: Pazopanib results in the longest weighted median PFS, after previous IO-failure, regardless of treatment line, as well as in specific second-line, post-first-line IO failure settings. Pending novel studies, Pazopanib appears to represent the most promising treatment option after prior IO.

AB - BACKGROUND: The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void.MATERIAL AND METHODS: We systematically examined TKI efficacy after IO-failure and generated weighted median progression-free survival (PFS) estimates for Pazopanib, Axitinib, Cabozantinib, Sunitinib. A systematic review according to PRISMA was conducted. PubMed and abstracts were queried. Only studies proving median PFS were included. Weighted medians were computed for each TKI alternative.RESULTS: Of 245 articles, nine eligible studies were included in the current study with 952 analysed patients. Weighted PFS medians after any previous IO-based therapy were respectively 13.7 (range from 4.6 to 24.4), 8.1 (range from 4.7 to 13.2), 8.5 (range from 4.7 to 15.2) and 6.9 months (range from 2.9 to 11.6) for Pazopanib, Axitinib, Cabozantinib, Sunitinib. Specific second-line weighted PFS median was 14.8 months (range from 5.6 to 24.4), 10.1 months (range from 6.4 to 13.2), 8.7 months (range from 4.7 to 15.2) and 6.0 months (range from 2.9 to 8.0) for Pazopanib, Axitinib, Cabozantinib, Sunitinib, respectively, after first-line IO.CONCLUSION: Pazopanib results in the longest weighted median PFS, after previous IO-failure, regardless of treatment line, as well as in specific second-line, post-first-line IO failure settings. Pending novel studies, Pazopanib appears to represent the most promising treatment option after prior IO.

KW - Female

KW - Humans

KW - Kidney Neoplasms/drug therapy

KW - Male

KW - Neoplasm Metastasis

KW - Protein Kinase Inhibitors/pharmacology

KW - Time Factors

U2 - 10.1016/j.ejca.2021.07.014

DO - 10.1016/j.ejca.2021.07.014

M3 - SCORING: Review article

C2 - 34392067

VL - 155

SP - 245

EP - 255

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -